Kisqali (ribociclib): The 2031-2036 Generic Opportunity Window

Novartis and Astex Pharmaceuticals' Kisqali (ribociclib succinate) is a blockbuster cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of HR-positive, HER2-negative breast cancer (FDA NDA 209092). Kisqali generated $4.8 billion in full-year 2025 global net sales, reflecting a massive 57% year-over-year growth. The core composition-of-matter and substance patents (U.S. Patent Nos. 8,324,225; 8,415,355; and 8,685,980) expire between March 2028 and March 2031. However, the critical secondary solid-state salt patent, U.S. Patent No. 9,193,732, which explicitly covers the commercial crystalline ribociclib succinate formulation, extends Orange Book protection through October 14, 2036. Today, Kisqali remains 100% Brand-only in the United States, with zero generic ribociclib approved for commercial sale. Multiple generic challengers, prominently including Natco Pharma, have filed Paragraph IV ANDA certifications challenging these patents to secure market entry. The 2031-2036 window represents a major generic opportunity, pending the resolution of ongoing patent litigation and settlements.